Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of the Use of Recombinant Human Growth Hormone on Attention Hyperactivity Deficit Characteristics in Children and Adolescents

NCT02973061 is registered in ClinicalTrials.gov with Assaf-Harofeh Medical Center as lead sponsor.

NCT NCT02973061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02973061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of the Use of Recombinant Human Growth Hormone on Attention Hyperactivity Deficit Characteristics in Children and Adolescents
Lead sponsor
Assaf-Harofeh Medical Center
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2015
Completion date
December 31, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit disorder, growth hormone deficiency, idiopathic short stature